Condition: Atrial Fibrillation · Sponsor: East and North Hertfordshire NHS Trust
Impaired endogenous fibrinolysis is a recently recognised risk factor for thrombotic events in patients with cardiovascular disease. Enhancing endogenous fibrinolysis in such individuals represents a way of reducing thrombosis risk. However, the optimal pharmacotherapy to enhance fibrinolysis is unclear. The aim of this study is to assess the effect of asundexian on endogenous fibrinolysis and compare this to apixaban. If asundexian can enhance endogenous fibrinolysis, this could be used as targeted treatment for patients who despite optimal antithrombotic therapy, demonstrate impaired endogenous fibrinolysis.
This description comes directly from the study's public registry record.
Joshua H Leader, MBCHB, BSc · 07376188768 · joshua.leader@nhs.net
Diana A Gorog, MD, PhD · 01707247512 · d.gorog@imperial.ac.uk
Always discuss trial participation with your own doctor first.
| Liverpool Heart and Chest Hospital | Liverpool, United Kingdom | Not Yet Recruiting |
| East and North Herts NHS Trust | Stevenage, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06124612